Lactobacillus reuteri Assists Engineered Bacteria That Target Tumors to Release PD‐L1nb to Mitigate the Adverse Effects of Breast Cancer Immunotherapy
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Programmed death protein‐ligand 1 (PD‐L1) inhibitors demonstrate significant antitumor efficacy by modulating T‐cell activity and inhibiting the PD‐1/PD‐L1 pathway, thus enhancing immune responses. Despite their robust effects, systemic administration of these inhibitors is linked to severe immune toxicity. To address this issue, we engineered a strain, REP, which releases PD‐L1 nanoantibodies (PD‐L1nb) to treat breast cancer and attenuate immunotherapy‐related side effects. REP selectively targets tumors and periodically releases PD‐L1nb within tumors via a quorum‐sensing lysis system. Administration of 108 colony‐forming units (CFU) of REP led to a substantial 52% reduction in tumor growth, achieved through the sustained release of PD‐L1nb. Importantly, there were no detectable lesions in other organs, with the exception of mild intestinal damage. Further, we explored the potential of a combined treatment using Lactobacillus reuteri (LR) and REP to alleviate intestinal inflammation. LR modulates the expression of inflammatory markers IL‐1β, IL‐6, and IL‐10 through the JNK pathway, reducing intestinal inflammation without compromising REP's antitumor efficacy. Consequently, we formulated a dual strategy employing an engineered strain and probiotics to reduce the adverse effects of immunotherapy in cancer treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, Yue et al. (2024) engineered a novel L. reuteri strain designed to selectively target tumors and release PD-L1 nanobodies in a breast cancer mouse model. By combining the two treatments, they decreased the adverse events of ICB treatment by alleviating intestinal inflammation.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Yue et al., 2024
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“However, systemic administration of PD-L1 inhibitors often leads to potent antitumor effectiveness accompanied by severe immune toxicity, with approximately 70% of patients experiencing adverse immune reactions such as rash, colitis, thyroid dysfunction, and hepatitis [3, 4].”
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396 · cited 1×
“Studies have demonstrated that PD-L1 expression is associated with triple-negative breast cancer [30–32], and PD-1/PD-L1 pathway inhibitors can induce durable clinical responses in some breast cancer patients with metastatic TNBC [33].”
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“Studies have shown that immune checkpoint blockade may alter the immune balance in the gut, leading to a decrease in probiotics such as Akkermansia and Lactobacillus , and an increase in inflammatory microbes such as Bacteroides and Burkholderiales , thereby exacerbating colitis [37, 38].”
Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body
Cristofori, F., Dargenio, V. N., Dargenio, C., Miniello, V. L., Barone, M., & Francavilla, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.578386 · Cited by 912 · cited 1×
“Through interactions with the host immune system, probiotics can regulate the intestinal microenvironment and enhance the secretion of anti-inflammatory cytokines in the gut, thereby promoting repair of gastrointestinal inflammatory damage [13].”
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905 · cited 2×
“…coli target the tumor microenvironment through complex mechanisms, such as trapping in the chaotic tumor vasculature following systemic injection, tropism for compounds produced by tumors, tumor localization following inflammation, and protection from clearance by the immune system [7–9].”
InfluentialLactobacillus reuteri induces gut intraepithelial CD4 + CD8αα + T cells
Cervantes-Barragan, L., Chai, J. N., Tianero, M. D., Di Luccia, B., Ahern, P. P., Merriman, J., Cortez, V. S., Caparon, M. G., Donia, M. S., Gilfillan, S., et al. (2017) · Science · doi:10.1126/science.aah5825 · Cited by 896 · cited 1×
“…some of which activate aryl hydrocarbon receptors (AhR) in group 3 innate lymphocytes (ILC3s) and CD4 + T cells, down-regulating and differentiating ThPOK into CD4 + CD8 𝛼𝛼 + double-positive intraepithelial lymphocytes to reprogram intraepithelial CD4 + T cells into immunomodulatory T cells [42].”
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 863 · cited 1×
“Studies have demonstrated that PD-L1 expression is associated with triple-negative breast cancer [30–32], and PD-1/PD-L1 pathway inhibitors can induce durable clinical responses in some breast cancer patients with metastatic TNBC [33].”
Synchronized cycles of bacterial lysis for in vivo delivery
Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., et al. (2016) · Nature · doi:10.1038/nature18930 · Cited by 784
Role of Lactobacillus reuteri in Human Health and Diseases
Mu, Q., Tavella, V. J., & Luo, X. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00757 · Cited by 744 · cited 1×
“Lactobacillus reuteri (LR) modulates the intestinal microenvironment to restore the intestinal symbiotic flora in inflammatory bowel disease and mitigates intestinal inflammation by suppressing the expression of pro-inflammatory factors in intestinal epithelial cells [14–17].”
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Chowdhury, S., Castro, S., Coker, C., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0498-z · Cited by 724 · cited 1×
“For instance, Danino et al. [11] have developed a lysis sys-tem based on quorum-sensing components to regulate bacterial density and facilitate the release of immune checkpoint inhibitors through lysis.”
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530 · cited 1×
“…coli target the tumor microenvironment through complex mechanisms, such as trapping in the chaotic tumor vasculature following systemic injection, tropism for compounds produced by tumors, tumor localization following inflammation, and protection from clearance by the immune system [7–9].”
InfluentialYan, F., & Polk, D. B. (2011) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834baa4d · Cited by 447 · cited 1×
“Bifidobacterium infantis can alleviate inflammation and promote intestinal healing by inhibiting the production of pro-inflammatory cytokines suchasTNF-α andIL-6[43].”
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400 · cited 1×
“Another advantage of bacterial treatments is that they are sensitive to antibiotics and can be eliminated by antibiotics [36].”
A sensing array of radically coupled genetic ‘biopixels’
Prindle, A., Samayoa, P., Razinkov, I., Danino, T., Tsimring, L. S., & Hasty, J. (2012) · Nature · doi:10.1038/nature10722 · Cited by 397 · cited 2×
“pTD103luxI_sfGFP was a gift from Jeff Hasty [19]. ePop was a gift from Lingchong You [20].”
Nishijima, T. F., Shachar, S. S., Nyrop, K. A., & Muss, H. B. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0419 · Cited by 300
Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., Al-Alwan, M., & Ghebeh, H. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0421-2 · Cited by 285
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.016 · Cited by 283 · cited 1×
“Breast cancer is the most prevalent malignancy among women and its various subtypes exhibit differential responses to distinct therapeutic interventions [26–29].”
Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer
Yi, X., Zhou, H., Chao, Y., Xiong, S., Zhong, J., Chai, Z., Yang, K., & Liu, Z. (2020) · Science Advances · doi:10.1126/sciadv.aba3546 · Cited by 276 · cited 1×
“Many biosafety studies have consistently demonstrated that intravenously administered engineered bacteria possess tumor-homing characteristics and that toxicity to the host is also insignificant [6, 24, 25, 35].”
Ultrasound-controllable engineered bacteria for cancer immunotherapy
Abedi, M. H., Yao, M. S., Mittelstein, D. R., Bar-Zion, A., Swift, M. B., Lee-Gosselin, A., Barturen-Larrea, P., Buss, M. T., & Shapiro, M. G. (2022) · Nature Communications · doi:10.1038/s41467-022-29065-2 · Cited by 260 · cited 2×
“Recent studies have demonstrated that intravenous injection of microorganismscanselectivelycolonizetumorswithoutaffecting host health [6].”
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Soliman, H., Khalil, F., & Antonia, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088557 · Cited by 245 · cited 1×
“Studies have demonstrated that PD-L1 expression is associated with triple-negative breast cancer [30–32], and PD-1/PD-L1 pathway inhibitors can induce durable clinical responses in some breast cancer patients with metastatic TNBC [33].”
Leschner, S., Westphal, K., Dietrich, N., Viegas, N., Jablonska, J., Lyszkiewicz, M., Lienenklaus, S., Falk, W., Gekara, N., Loessner, H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006692 · Cited by 236
Recent therapeutic trends and promising targets in triple negative breast cancer
Hwang, S.-Y., Park, S., & Kwon, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.006 · Cited by 232
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.4 · Cited by 226
Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade
Wang, F., Yin, Q., Chen, L., & Davis, M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712901115 · Cited by 223 · cited 1×
“Bifidobacterium hasalsobeenshown to improve intestinal immunopathology associated with CTLA4 blockade [44].”
Abou Khouzam, R., Brodaczewska, K., Filipiak, A., Zeinelabdin, N. A., Buart, S., Szczylik, C., Kieda, C., & Chouaib, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613114 · Cited by 198
Chen, Y., Du, M., Yuan, Z., Chen, Z., & Yan, F. (2022) · Nature Communications · doi:10.1038/s41467-022-31932-x · Cited by 189
Self-citationChemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity
Savage, T. M., Vincent, R. L., Rae, S. S., Huang, L. H., Ahn, A., Pu, K., Li, F., de los Santos-Alexis, K., Coker, C., Danino, T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adc9436 · Cited by 161 · cited 1×
“Many biosafety studies have consistently demonstrated that intravenously administered engineered bacteria possess tumor-homing characteristics and that toxicity to the host is also insignificant [6, 24, 25, 35].”
Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity
Ozdemir, T., Fedorec, A. J. H., Danino, T., & Barnes, C. P. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.008 · Cited by 159
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hayashi, H., & Nakagawa, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01548-1 · Cited by 156
Wang, G., Huang, S., Cai, S., Yu, H., Wang, Y., Zeng, X., & Qiao, S. (2020) · Nutrients · doi:10.3390/nu12082298 · Cited by 115 · cited 2×
“Lactobacillus reuteri (LR) modulates the intestinal microenvironment to restore the intestinal symbiotic flora in inflammatory bowel disease and mitigates intestinal inflammation by suppressing the expression of pro-inflammatory factors in intestinal epithelial cells [14–17].”
Sun, M.-C., Zhang, F., Yin, X., Cheng, B., Zhao, C., Wang, Y., Zhang, Z., Hao, H., Zhang, T., & Ye, H. (2018) · Journal of Food Science · doi:10.1111/1750-3841.14326 · Cited by 103
Liu, X., Guo, C., Tou, F., Wen, X., Kuang, Y., Zhu, Q., & Hu, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32744 · Cited by 87
Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering
Mishra, J., Stubbs, M., Kuang, L., Vara, N., Kumar, P., & Kumar, N. (2022) · Mediators of Inflammation · doi:10.1155/2022/9621668 · Cited by 81 · cited 1×
“Probiotics are widely utilized to manage chronic inflammatory diseases such as colitis by inhibiting the release of cellular inflammatory factors and upregulating the expression of anti-inflammatory factors [12].”
The potential therapeutic role of Lactobacillus reuteri for treatment of inflammatory bowel disease.
Wang, H., Zhou, C., Huang, J., Kuai, X., & Shao, X. (2020) · PubMed Central · Cited by 68
Oscillations by Minimal Bacterial Suicide Circuits Reveal Hidden Facets of Host-Circuit Physiology
Marguet, P., Tanouchi, Y., Spitz, E., Smith, C., & You, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011909 · Cited by 65
Schreiber, O., Petersson, J., Phillipson, M., Perry, M., Roos, S., & Holm, L. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90470.2008 · Cited by 57 · cited 1×
“For instance, LR can also alleviate DSS-induced colitis by attenuating P- selectin-mediated interactions between leukocytes and platelet endothelial cells, regulating the structure of gut microbiota, and ameliorating metabolic disorders [17, 18].”
Han, C., Zhang, X., Pang, G., Zhang, Y., Pan, H., Li, L., Cui, M., Liu, B., Kang, R., Xue, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121619 · Cited by 52 · cited 1×
“Furthermore, immune checkpoint-related colitis decreases the abundance of lactic acid bacteria in the intestinal microbiota of mice [39].”
Self-citationDóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 51
Checkpoint Inhibitor-Induced Colitis: An Update
Losurdo, G., Angelillo, D., Favia, N., Sergi, M. C., Leo, A. D., Triggiano, G., & Tucci, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051496 · Cited by 30 · cited 1×
“The mechanism underlying this intestinal damage may beattributedtotheabilityofimmunecheckpointinhibitors(ICIs) to enhance antitumor immunity while simultaneously triggering abnormal immune responses against self-antigens within the intestines [5].”
Xu, Y., Wang, H., Zhang, X., Zheng, X., Zhu, Y., Han, H., & Feng, W.-H. (2021) · Veterinary Microbiology · doi:10.1016/j.vetmic.2021.109061 · Cited by 29 · cited 1×
“In previous studies, IL-6 has been proven to be regulated through the JNK pathway [40, 41].”
Kim, M., Han, J.-Y., Kim, S., Kim, H. Y., Jeon, D., & Lee, K. (2018) · The Journal of Toxicological Sciences · doi:10.2131/jts.43.485 · Cited by 17 · cited 1×
“In previous studies, IL-6 has been proven to be regulated through the JNK pathway [40, 41].”
Glucose oxidase virus‐based nanoreactors for smart breast cancer therapy
Gama, P., Juárez, P., Rodríguez‐Hernández, A. G., & Vázquez-Duhalt, R. (2023) · Biotechnology Journal · doi:10.1002/biot.202300199 · Cited by 13 · cited 1×
“Breast cancer is the most prevalent malignancy among women and its various subtypes exhibit differential responses to distinct therapeutic interventions [26–29].”
Saji, S., Ohsumi, S., Ito, M., Hayashi, N., Kobayashi, K., Masuda, N., Niikura, N., Yamashita, T., Kiyama, K., Hasegawa, A., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac098 · Cited by 10
Thevendran, R., & Solayappan, M. (2023) · Biotechnology Journal · doi:10.1002/biot.202300077 · Cited by 7 · cited 1×
“Based on this characteristic of E. coli , genetically engineered bacteria have been designed to locally release therapeutic molecules within the tumor microenvironment, thereby minimizing systemic adverse effects [10].”
Cited by
Microbial modulation as a game changer: Boosting immunotherapy efficacy in breast cancer
Xia, F., Yi, Q., Xu, Z., Zhou, Z., Tang, H., Zhang, K., & Yan, Y. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.006 · Cited by 27
Microbiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy
Sabeel, Z., & Zhao, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02456-x · Cited by 21
“Lactobacillus reuteri ( L. reuteri) , a natural component of breast milk, has been shown to suppress BC cell proliferation and modulate host immune responses [108].”
Nama, A. A., Sandeepa, G. M., Viswanath, B., & Mastan, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177410 · Cited by 12
Covalent organic frameworks for cancer immunotherapy: mechanisms, applications, and prospects
Zou, Y., Chen, M., Chen, J., Wang, W., & Zheng, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1719005 · Cited by 9
Metadata
- Authors
- Yue, L., Geng, F., Jin, J., Li, W., Liu, B., Du, M., Gao, X., Lü, J., & Pan, X.
- Affiliations
- Binzhou Medical University (CN)
- Corresponding author
- Geng, Feng
- Pan, Xiaohong
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2024-12
- Volume
- 19
- Issue
- 12
- Pages
- e202400428-e202400428
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W4405727760
- Cited by
- 14
- References
- 45
- Citations by year
- 2026: 9 · 2025: 5
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biotechnology Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Natural Science Foundation of Shandong Province (ZR2022MC121)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- Lactobacillus reuteri, engineered bacteria, breast cancer, immune checkpoint inhibitors, immunotherapy toxicity, probiotics, intestinal inflammation, JNK signaling, IL-1β, interleukin-6, IL-10, tumor growth inhibition
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Breast Neoplasms, Female, Humans, Immunotherapy, Mice, Inbred BALB C, Cell Line, Tumor, Mice, Limosilactobacillus reuteri, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.